# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Demyelinating Diseases

Hypomyelination
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 486 results.
Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions
Status: Recruiting
Last Changed: Jul 29, 2019
First Received: Aug 31, 2017
Disease(s): Magnetic Resonance Imaging, Central Nervous System, Brain, Multiple Sclerosis, Demyelinating Diseases
Intervention(s): Additional MRI sequences
Locations: Fondation Ophtalmologique A. de Rothschild, Paris, France
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis
Status: Recruiting
Last Changed: Dec 17, 2019
First Received: Dec 17, 2019
Disease(s): Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Controls, Multiple Sclerosis
Intervention(s): Blood withdrawal, MRI, Neurologic / neuropsychologic tests - Patients, Neurologic / neuropsychologic tests - Controls
Locations: CHU Montpellier, Montpellier, France
Disability, MRI Lesions and Thickness of Retinal Fibers: Evaluation 15 Years After a First Episode of Demyelination
Status: Recruiting
Last Changed: Jun 14, 2019
First Received: Aug 31, 2017
Disease(s): Multiple Sclerosis, Pathologic Processes, Tomography, Optical Coherence, Magnetic Resonance Imaging, Prognosis
Intervention(s): Cerebral MRI and Optical Coherence Tomography
Locations: Fondation Ophtalmologique A. de Rothschild, Paris, France
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
Status: Recruiting
Last Changed: Oct 28, 2019
First Received: Jun 20, 2018
Disease(s): Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases, Autoimmune Diseases, Immune System Diseases, Primary Progressive Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Intervention(s): Ocrelizumab
Locations: Carol and Frank Morsani Center for Advanced Healthcare, Tampa, Florida, United States
Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions
Status: Recruiting
Last Changed: Aug 08, 2019
First Received: Oct 20, 2016
Disease(s): Multiple Sclerosis, Autoimmune
Intervention(s): Microcannula Harvest Adipose, Centricyte 1000, Sterile Normal Saline IV deployment AD-cSVF
Locations: Regenevita LLC, Stevensville, Montana, United States
Global Alliance for Regenerative Medicine (GARM), Roatan, Hn, Honduras
Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients
Status: Recruiting
Last Changed: Sep 13, 2018
First Received: Aug 01, 2018
Disease(s): Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome, Clinically Isolated Syndrome, CNS Demyelinating, Vitamin D3 Deficiency
Intervention(s): Vitamin D3
Locations: Nehme & Therese Tohme Multiple Sclerosis Center, Beirut, Lebanon
Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis
Status: Recruiting
Last Changed: Jan 14, 2020
First Received: May 30, 2018
Disease(s): Sclerosis, Multiple, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases
Intervention(s): Melatonin, Placebo
Locations: Virgen Macarena Hospital, Seville, Spain
Hospital Vithas Nisa Sevilla, Seville, Spain
Cognition and MRI Markers in MS Patients With Aubagio® Treatment
Status: Recruiting
Last Changed: Jul 17, 2019
First Received: Dec 07, 2018
Disease(s): Multiple Sclerosis, Relapsing-Remitting
Intervention(s): Clinical assessment, Ecological evaluation, Neuropsychological evaluation, Psychological evaluation, MRI Evaluation
Locations: CHU de Bordeaux - Service de neurologie, Bordeaux, France
Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP
Status: Recruiting
Last Changed: Jan 13, 2020
First Received: Sep 15, 2015
Disease(s): Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention(s): HYQVIA, 0.25% albumin placebo solution with rHuPH20, IGIV
Locations: Barrow Neurological Institute, Phoenix, Arizona, United States
Arizona Neuromuscular Research Center, Phoenix, Arizona, United States
University of Colorado - UC Health Medical Campus, Aurora, Colorado, United States
University of South Florida - Parent, Tampa, Florida, United States
Neurology Center of Las Vegas, Las Vegas, Nevada, United States
... and 77 other locations.
Behavior and Activity Monitoring in MS
Status: Recruiting
Last Changed: Jan 29, 2019
First Received: Aug 09, 2017
Disease(s): Relapsing-Remitting Multiple Sclerosis
Intervention(s): Step Tracking, Water Tracking
Locations: Department of Psychology, The Ohio State University, Columbus, Ohio, United States